Genome-wide association study for circulating metabolites in 619,372 individuals

Ralf Tambets,Jaanika Kronberg,Erik Abner,Urmo Võsa,Ida Rahu,Nele Taba,Anastassia Kolde,Estonian Biobank Research Team,Krista Fischer,Tõnu Esko,Kaur Alasoo,Priit Palta

DOI: https://doi.org/10.1101/2024.10.15.24315557

2024-10-16

Abstract:Examining the upstream molecular consequences of genetic variation significantly enhances our understanding of the heritable determinants of complex traits and disease predisposition. Metabolites serve as key indicators of various biological processes and disease states, playing a crucial role in this systematic mapping, also providing opportunities for the discovery of new biomarkers for disease diagnosis and prognosis. Here, we present a genome-wide association study for 249 circulating metabolite traits quantified by nuclear magnetic resonance spectroscopy across various genetic ancestry groups from the Estonian Biobank and the UK Biobank. We generated mixed model associations in the Estonian Biobank and six major genetic ancestry groups of the UK Biobank and performed two separate meta-analyses across the predominantly European genetic ancestry samples (n = 599,249) and across all samples (n = 619,372). In total, we identified 89,489 locus-metabolite pairs and 8,917 independent lead variants, out of which 4,184 appear to be novel associated loci. Moreover, 12.4% of the independent lead variants had a minor allele frequency of less than 1%, highlighting the importance of including low-frequency and rare variants in metabolic biomarker studies. Our publicly available results provide a valuable resource for future GWAS interpretation and drug target prioritisation studies.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to systematically explore and identify genetic variant loci associated with circulating metabolites through genome - wide association studies (GWAS). Specifically, the researchers utilized a large amount of sample data from the Estonian biobank and the UK biobank to analyze 249 circulating metabolites determined by nuclear magnetic resonance spectroscopy, aiming at:

1. **Discovering new genetic associations**: By increasing the sample size and improving statistical power, the researchers hope to identify more previously undiscovered genetic loci associated with metabolite levels.

2. **Evaluating the role of low - frequency and rare variants**: In addition to common genetic variants, the study also pays special attention to the impact of low - frequency and rare variants on metabolite levels, which helps to more comprehensively understand the impact of genetic variants on metabolite levels.

3. **Providing resources to support future research**: The research results will serve as an open resource, providing an important reference for future GWAS interpretation and drug target prioritization research.

Through these efforts, the researchers hope to enhance the understanding of the genetic determinants of complex traits and disease susceptibility, and at the same time provide new biomarkers for disease diagnosis, prognosis and treatment.